

## Drugs on the Anticholinergic Burden (ACB) scale

(A total ACB scale score of three or more is considered clinically relevant)

ACB Score 1 (mild)	ACB Score 2 (moderate)	ACB Score 3 (severe)
Alimemazine	Amantadine	Amitriptyline
Alprazolam	Belladonna alkaloids	Amoxapine
Alverine	Carbamazepine	Atropine
Atenolol	Cyclobenzaprine	Benztropine
Beclometasone dipropionate	Cyproheptadine	Chlorpheniramine
Bupropion hydrochloride	Loxapine	Chlorpromazine
Captopril	Meperidine	Clemastine
Chlorthalidone	Methotrimeprazine	Clomipramine
Cimetidine hydrochloride	Molindone	Clozapine
Clorazepate	Oxcarbazepine	Darifenacin
Codeine	Pethidine hydrochloride	Desipramine
Colchicine	Pimozide	Dicyclomine
Dextropropoxyphene		Diphenhydramine
Diazepam		Doxepin
Digoxin		Flavoxate
Dipyridamole		Hydroxyzine
Disopyramide phosphate		Hyoscyamine
Fentanyl		Imipramine
Fluvoxamine		Meclizine
Furosemide		Nortriptyline
Haloperidol		Orphenadrine
Hydralazine		Oxybutynin
Hydrocortisone		Paroxetine
Isosorbide preparations		Perphenazine
Loperamide		Procyclidine
Metoprolol		Promazine
Morphine		Promethazine
Nifedipine		Propentheline
Prednisone/Prednisolone		Pyrilamine
Quinidine		Scopolamine
Ranitidine		Thioridazine (withdrawn)
Theophylline		Tolterodine
Timolol maleate		Trifluoperazine
Trazodone		Trihexyphenidyl
Triamterene		Trimipramine
Warfarin		

### Notes:

1. Certain medicines eg *Risperidone (mild ACB)*, *Quetiapine (severe ACB)* and *Olanzapine (severe ACB)* were licensed after 1990 and therefore not prescribed to the original CFAS cohort.
2. Brand names may conceal generic drug names.
3. Some combination medicines contain anticholinergic drugs.
4. This list is indicative and some related medicines were taken by patients in the CFAS study; if appropriate these related medicines were given an ACB score based on the ACB of the related medicine in the *Aging Health* publication (see below).

### References:

1. Boustani MA, Campbell NL, Munger S, Maidment I, Fox GC. Impact of anticholinergics on the aging brain: a review and practical application. *Aging Health*. 2008;4(3):311-20.
2. Campbell N, Boustani M, Limbil T, Ott C, et al. The cognitive impact of anticholinergics: a clinical review. *Clinical Interventions in Aging*. 2009;4(1):225-33